Zykadia® (ceritinib) – Expanded indication
May 26, 2017 – Novartis announced the FDA approval of Zykadia (ceritinib) for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test.
Download PDF
